about
mTOR inhibitors in advanced renal cell carcinomaCCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signalingTherapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.New immunosuppressive drugs and lung transplantation: last or least?Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.New immunosuppressive drugs: mechanistic insights and potential therapeutic advancesSirolimus: a comprehensive review.Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions.Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignanciesImmunostimulatory activity of lifespan-extending agents.Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: possible clinical application of rapamycin.Everolimus and sirolimus in transplantation-related but different.Management of High-risk Corneal Transplantation.Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.Methionine interference in rapamycin production involves repression of demethylrapamycin methyltransferase and S-adenosylmethionine synthetase.Pharmacologic control of a humanized gene therapy system implanted into nude mice.Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts.Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptorSirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.Xenotransplantation of hepatocytes in rats with acute liver failure using sirolimus for immunosuppression.Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome.Secondary metabolism in simulated microgravity.Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway.Clinical development of mTor inhibitors for renal cancer.The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).MTOR signaling is essential for the development of thymic epithelial cells and the induction of central immune tolerance.Possible molecular target therapy with rapamycin in MDS.
P2860
Q24612127-10F0C932-458F-459A-B72A-F7574312F443Q24672058-C9AC0818-8D33-4135-B838-2A9AF6949065Q33332141-3F608F30-290D-40F1-8655-2EA47BE72C6BQ33338797-6E30F3D2-BE12-45E4-8379-0BA68657620AQ33639354-0F940033-F24B-4210-B602-95945E35D1B1Q33776274-C949D98F-8AB7-4781-910E-3332F884A90DQ34275358-269D7745-DE8C-4AEA-A639-6A2753237A98Q34515537-5116445B-5DE2-41F1-BDB0-16CD8057AE2CQ36614145-070AE097-1B3A-481F-9073-CBEE1E648381Q37195644-BEE96789-B3D7-44AD-A60B-B17C7296638BQ38175673-7615AF6A-F3AB-4105-9A6A-301E500E77D7Q38351488-9D1083D2-18D4-41F1-B441-17A2DA61EC22Q38442560-D21626B5-2E5C-4564-98DE-E94DB8853321Q38778422-E22A1CF2-44CB-4D6F-971B-C127A5F7D8FAQ38904800-C527EA2B-461F-4C59-8F81-2AACE44A97F1Q39475531-8801D7C5-E660-45B2-B92A-413CF2AC4B56Q39795171-5AC26F69-6CF8-48CB-A33D-F38693BFAC10Q40446287-A515E0DE-5DD6-401F-A947-0D5F2E9E61AAQ41424778-C72333D4-2031-44BB-B4CF-545BC8DF82CFQ42680562-2E336DBB-49F3-4868-B89D-F96CB49F41DBQ43048720-D31EC0F5-11C9-4A63-8E62-95018B5F3AC5Q43258160-D49763B4-3736-49B6-BE63-AD0836497D35Q43917035-A5276FC9-2008-48F6-8600-1659E51DCBE9Q45985298-683D3474-F399-465D-A016-AE673B3B2C3AQ47601570-D83CFF3A-3C65-4A67-8526-EA413051D153Q47737687-528E6CB6-957B-45FD-B03B-5B8A4D924B85Q50649002-480600B9-DA1E-4B17-83DA-79ABCE0E76AAQ51790263-EAE62153-B315-4962-97A7-F300F0585855Q54598386-565EEDAF-94CD-4933-873C-A2C50E940F47
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Rapamycin: a novel immunosuppressive macrolide.
@en
type
label
Rapamycin: a novel immunosuppressive macrolide.
@en
prefLabel
Rapamycin: a novel immunosuppressive macrolide.
@en
P2093
P2860
P356
P1476
Rapamycin: a novel immunosuppressive macrolide.
@en
P2093
Molnar-Kimber K
Weichman BM
P2860
P356
10.1002/MED.2610140102
P577
1994-01-01T00:00:00Z